Vebicorvir
Based on 2 publication(s) in Google Scholar
Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC50s from 1.84 μM to 7.3 μM.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.43%
- CAS. Nr.: 2090064-66-5
- Formel: C19H12F3N3O4S2
- Molecular Weight:467.44
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-109168
BersacapavirHBV Inhibitor -
HY-108917
MorphothiadinHBV Inhibitor -
HY-124614
GLP-26HBV Capsid Effector -
HY-117650A
RG7834HBV Inhibitor -
HY-13623
EntecavirHBV Inhibitor -
HY-16679
Helioxanthin derivative 5-4-2HBV Inhibitor -
HY-112142
AB-423 -
HY-116999
IR415Anti-HBV Inhibitor -
HY-101954
InarigivirHBV Inhibitor -
HY-N1365
IsoscopoletinHBV Inhibitor -
HY-126970
HBF-0259HBsAg Secretion Inhibitor -
HY-114314
BA-53038BHBV Core Protein Allosteric Modulator
Publications Citing Use of MedChemExpress (MCE) Vebicorvir
More
Biologische Aktivität
Beschreibung
In Vitro
Vebicorvir (ABI-H0731) demonstrates inhibition of pgRNA, HBeAg, and HBsAg production, with EC50s of 2.68 μM, 4.95 μM, and 7.30 μM, respectively[1].
Vebicorvir (ABI-H0731) is an inhibitor of pgRNA encapsidation and rcDNA synthesis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 2090064-66-5
-
Appearance Solid
-
Molecular Weight 467.44
-
Formel C19H12F3N3O4S2
-
Color White to off-white
-
SMILES
O=C(C1=CC=C(C(NC(C2=CC=CC=C23)=O)=C1)S3(=O)=O)NCC4=CN=C(C(F)(F)F)S4
-
Synonyms
ABI-H0731
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
PLoS Pathog
HBV capsid assembly modulators differentially modulate the assembly of wild-type and drug-resistant core protein chimeric nucleocapsids and empty capsids. [Abstract]2025 Aug 5;21(8):e1013391. PMID: 40763308 -
Anal Methods
An automated microfluidic platform for the screening and characterization of novel hepatitis B virus capsid assembly modulators. [Abstract]2022 Jan 6;14(2):135-146. PMID: 34918017
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (213.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.45 mM); Suspended solution
This protocol yields a suspended solution of ≥ 2.08 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (275 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1393 mL | 10.6966 mL | 21.3931 mL | 53.4828 mL |
| 5 mM | 0.4279 mL | 2.1393 mL | 4.2786 mL | 10.6966 mL | |
| 10 mM | 0.2139 mL | 1.0697 mL | 2.1393 mL | 5.3483 mL | |
| 15 mM | 0.1426 mL | 0.7131 mL | 1.4262 mL | 3.5655 mL | |
| 20 mM | 0.1070 mL | 0.5348 mL | 1.0697 mL | 2.6741 mL | |
| 25 mM | 0.0856 mL | 0.4279 mL | 0.8557 mL | 2.1393 mL | |
| 30 mM | 0.0713 mL | 0.3566 mL | 0.7131 mL | 1.7828 mL | |
| 40 mM | 0.0535 mL | 0.2674 mL | 0.5348 mL | 1.3371 mL | |
| 50 mM | 0.0428 mL | 0.2139 mL | 0.4279 mL | 1.0697 mL | |
| 60 mM | 0.0357 mL | 0.1783 mL | 0.3566 mL | 0.8914 mL | |
| 80 mM | 0.0267 mL | 0.1337 mL | 0.2674 mL | 0.6685 mL | |
| 100 mM | 0.0214 mL | 0.1070 mL | 0.2139 mL | 0.5348 mL |
Vebicorvir Related Classifications
HY-109195 Related Classifications
Powered by Bioz